81 related articles for article (PubMed ID: 8927264)
21. [Clinico-genetic aspects of the hypotensive response and regression of left ventricular hypertrophy in arterial hypertension patients].
Moiseev VS; Kotovskaia IuV; Kobalava ZhD; Nosikov VV; Korovina EP; Timofeeva SG
Ter Arkh; 2002; 74(10):30-7. PubMed ID: 12469628
[TBL] [Abstract][Full Text] [Related]
22. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
[TBL] [Abstract][Full Text] [Related]
23. Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy.
Rosendorff C; Dubiel R; Xu J; Chavanu KJ
Am J Cardiol; 2009 Aug; 104(3):359-65. PubMed ID: 19616668
[TBL] [Abstract][Full Text] [Related]
24. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
[TBL] [Abstract][Full Text] [Related]
25. Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension.
Hui Y; Dai Z; Chen X; Wang W
Chin Med J (Engl); 1995 Sep; 108(9):678-81. PubMed ID: 8575234
[TBL] [Abstract][Full Text] [Related]
26. Effects of drug therapy on hypertensive left ventricular hypertrophy.
Fletcher PJ; Horvath JS; Bailey BP; Tiller D
Clin Exp Pharmacol Physiol; 1985; 12(3):291-4. PubMed ID: 3161673
[TBL] [Abstract][Full Text] [Related]
27. [The regression of left ventricular hypertrophy and improvement in diastolic filling during antihypertensive therapy with cilazapril].
Sabatini D; Fazio S; Cittadini A; Biondi B; Lucariello A; Picano T; Saccà L
Cardiologia; 1993 Jun; 38(6):377-81. PubMed ID: 8402747
[TBL] [Abstract][Full Text] [Related]
28. [The effect of nifedipine in hypertensive cardiopathy. An echocardiographic and electrocardiographic study].
Sau F; Seguro C; Lai C; Onnis E; Orani E; Soro A; Leo MR; Cherchi A
Cardiologia; 1993 Jun; 38(6):369-76. PubMed ID: 8402746
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension].
Puddu P; Gallucci M; Curnis A; Pupita F; Ansuini R; Malacco E
Clin Ter; 1995 Dec; 146(12):801-10. PubMed ID: 8681500
[TBL] [Abstract][Full Text] [Related]
30. [Effect of treatment with chlorthalidone on reduction of left ventricular mass in patients with systemic arterial hypertension].
Ramires JA; Mansur Ade P; Oigman W; Francischetti E; César LA; Marcondes M; da Luz PL; Pileggi F
Arq Bras Cardiol; 1993 Jun; 60(6):433-5. PubMed ID: 8279986
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy and tolerance of doxazosin in the treatment of isolated systolic hypertension in hypertensive patients over 60 years of age].
Calvo C; López E; Barrio E; Espejo J; Ruiz M; Vega A
An Med Interna; 1995 Mar; 12(3):122-6. PubMed ID: 7795118
[TBL] [Abstract][Full Text] [Related]
32. [Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism].
Sznajderman M; Chotkowska E; Peczkowska M; Sawicki M; Janaszek-Sitkowska H; Wiernikowska-Wegorek I; Galewicz A; Cybulska I
Kardiol Pol; 1993 Feb; 38(2):107-11. PubMed ID: 8230980
[TBL] [Abstract][Full Text] [Related]
33. Effects of sustained-release isradipine on left ventricular anatomy and function in systemic hypertension.
Bignotti M; Gaudio G; Gorini G; Rinaldi O; Grandi AM; Venco A
Am J Cardiol; 1993 Dec; 72(17):1301-4. PubMed ID: 8256708
[TBL] [Abstract][Full Text] [Related]
34. One-year antihypertensive treatment with amlodipine: effects on 24-hour blood pressure and left ventricular anatomy and function.
Bignotti M; Grandi AM; Gaudio G; Guasti L; Venco A
Acta Cardiol; 1995; 50(2):135-42. PubMed ID: 7610736
[TBL] [Abstract][Full Text] [Related]
35. Cardiac morphology and function in arterial hypertension. The effects of a new multifactorial hypotensive agent: urapidil.
Ghione S; Genovesi-Ebert A; Marabotti C; Spinazzi A; Noseda A
Blood Press Suppl; 1994; 4():25-30. PubMed ID: 7804509
[TBL] [Abstract][Full Text] [Related]
36. Effects of antihypertensive therapy on blood pressure and left ventricular hypertrophy in patients with severe hypertension.
Sumino H; Nakamura T; Kanda T; Sakamaki T; Sato K; Saito Y; Hoshino J; Kurashina T; Ono Z; Takahashi T; Ichikawa S; Kurabayashi M; Nagai R
Jpn Heart J; 2000 May; 41(3):339-48. PubMed ID: 10987352
[TBL] [Abstract][Full Text] [Related]
37. Reproducibility and clinical value of the trough-to-peak ratio of the antihypertensive effect: evidence from the sample study.
Omboni S; Fogari R; Palatini P; Rappelli A; Mancia G
Hypertension; 1998 Sep; 32(3):424-9. PubMed ID: 9740606
[TBL] [Abstract][Full Text] [Related]
38. Microalbuminuria as a marker of preclinical diastolic dysfunction in never-treated essential hypertensives.
Grandi AM; Santillo R; Bertolini A; Imperiale D; Broggi R; Colombo S; Selva E; Jessula A; Guasti L; Venco A
Am J Hypertens; 2001 Jul; 14(7 Pt 1):644-8. PubMed ID: 11465648
[TBL] [Abstract][Full Text] [Related]
39. Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for 6 months.
Gerdts E; Svarstad E; Aanderud S; Myking OL; Lund-Johansen P; Omvik P
Am J Hypertens; 1998 Oct; 11(10):1178-87. PubMed ID: 9799034
[TBL] [Abstract][Full Text] [Related]
40. Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient.
Pool JL
Br J Clin Pract Suppl; 1994 May; 74():8-12. PubMed ID: 8049119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
